Fulgent Genetics, Inc.

Fulgent Genetics, Inc. is a technology-based company primarily focused on providing comprehensive genetic testing services to deliver clinically actionable diagnostic information. Founded in 2011, the company's mission is to develop flexible and affordable diagnostics and therapeutics to improve patient care. Its headquarters are located in El Monte, California.

The company leverages proprietary technology platforms that integrate sophisticated data comparison algorithms, adaptive learning software, Next-Generation Sequencing (NGS) capabilities, and integrated laboratory processes. Fulgent Genetics offers an extensive test menu, including over 18,000 single-gene tests and numerous multi-gene and disease-specific panels for conditions such as various cancers, cardiovascular diseases, neurological disorders, and pediatric conditions. Additionally, it operates Picture Genetics, a consumer-oriented subsidiary for at-home genetic testing, and has a therapeutic development business focused on creating drug candidates for a broad range of cancers.

Led by founder, Chairman, and CEO Ming Hsieh, Fulgent Genetics has been actively expanding its capabilities. In March 2026, the company completed the acquisition of Bako Diagnostics and StrataDx, enhancing its pathology assets and laboratory footprint. While the first quarter of 2026 saw a modest revenue decline and wider losses, partly due to a major customer transitioning testing in-house, the company maintained its full-year revenue guidance. Fulgent Genetics is also advancing its therapeutic development pipeline, with clinical candidates FID-007 and FID-022, and aims to evolve into a fully integrated precision medicine company.